Literature DB >> 19133981

Decitabine is an effective treatment of idiopathic myelofibrosis.

Alexey V Danilov, Valerie Relias, Dianne M Feeney, Kenneth B Miller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19133981     DOI: 10.1111/j.1365-2141.2008.07541.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

Review 1.  Novel therapies for myelofibrosis.

Authors:  Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-05-18

Review 2.  Novel Therapies for Myelofibrosis.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

3.  Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.

Authors:  Daisuke Okamura; Akira Matsuda; Maho Ishikawa; Tomoya Maeda; Ken Tanae; Mika Kohri; Naoki Takahashi; Nobutaka Kawai; Norio Asou; Masami Bessho
Journal:  Leuk Res Rep       Date:  2014-04-16

4.  Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

Authors:  Claire Harrison; Alessandro M Vannucchi
Journal:  Ther Adv Hematol       Date:  2012-12

5.  Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.

Authors:  John Mascarenhas; Nitin Roper; Pratima Chaurasia; Ronald Hoffman
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

Review 6.  Definition and management of ruxolitinib treatment failure in myelofibrosis.

Authors:  A Pardanani; A Tefferi
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.